Literature DB >> 26063087

Australian Gonococcal Surveillance Programme annual report, 2013.

Monica M Lahra1.   

Abstract

The Australian Gonococcal Surveillance Programme has continuously monitored antimicrobial resistance in clinical isolates of Neisseria gonorrhoeae from all states and territories since 1981. In 2013, 4,897 clinical isolates of gonococci from public and private sector sources were tested for in vitro antimicrobial susceptibility by standardised methods. Decreased susceptibility to ceftriaxone (MIC value 0.06-0.125 mg/L) was found nationally in 8.8% of isolates, double that reported in 2012 (4.4%). The highest proportions were reported from New South Wales and Victoria (both states reporting 11.8%), with a high proportion of strains also reported from Tasmania but a low number of isolates were tested. In addition, there was a multi-drug-resistant strain of N. gonorrhoeae isolated from a traveller to Australia, with a ceftraixone MIC value of 0.5 mgL-the highest ever reported in Australia. These antimicrobial resistance data from Australia in 2013 are cause for considerable concern. With the exception of remote Northern Territory where penicillin resistance rates remain low (1.3%) the proportion of strains resistant to penicillin remained high in all jurisdictions ranging from 15.6% in the Australian Capital Territory to 44.1% in Victoria. Quinolone resistance ranged from 16% in the Australian Capital Territory to 46% in Victoria. Azithromycin susceptibility testing was performed in all jurisdictions and resistance ranged from 0.3% in the Northern Territory to 5.7% in Queensland. High level resistance to azithromycin (MIC value was > 256 mg/L) was reported for the first time in Australia, in 4 strains: 2 each from Queensland and Victoria. Azithromycin resistant gonococci were not detected in the Australian Capital Territory, Tasmania or from the remote Northern Territory. Nationally, all isolates remained susceptible to spectinomycin. This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Online, Services and External Relations Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or by email to copyright@health.gov.au.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26063087

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  8 in total

1.  Genomic Epidemiology and Molecular Resistance Mechanisms of Azithromycin-Resistant Neisseria gonorrhoeae in Canada from 1997 to 2014.

Authors:  Walter Demczuk; Irene Martin; Shelley Peterson; Amrita Bharat; Gary Van Domselaar; Morag Graham; Brigitte Lefebvre; Vanessa Allen; Linda Hoang; Greg Tyrrell; Greg Horsman; John Wylie; David Haldane; Chris Archibald; Tom Wong; Magnus Unemo; Michael R Mulvey
Journal:  J Clin Microbiol       Date:  2016-03-02       Impact factor: 5.948

2.  Decline in Decreased Cephalosporin Susceptibility and Increase in Azithromycin Resistance in Neisseria gonorrhoeae, Canada.

Authors:  I Martin; P Sawatzky; G Liu; V Allen; B Lefebvre; L Hoang; S Drews; G Horsman; J Wylie; D Haldane; R Garceau; S Ratnam; T Wong; C Archibald; M R Mulvey
Journal:  Emerg Infect Dis       Date:  2016-01       Impact factor: 6.883

3.  Azithromycin Resistance and Decreased Ceftriaxone Susceptibility in Neisseria gonorrhoeae, Hawaii, USA.

Authors:  John R Papp; A Jeanine Abrams; Evelyn Nash; Alan R Katz; Robert D Kirkcaldy; Norman P O'Connor; Pamela S O'Brien; Derek H Harauchi; Eloisa V Maningas; Olusegun O Soge; Ellen N Kersh; Alan Komeya; Juval E Tomas; Glenn M Wasserman; Gail Y Kunimoto; David L Trees; A Christian Whelen
Journal:  Emerg Infect Dis       Date:  2017-05       Impact factor: 6.883

4.  Susceptibility of Neisseria gonorrhoeae to azithromycin and ceftriaxone in China: A retrospective study of national surveillance data from 2013 to 2016.

Authors:  Yue-Ping Yin; Yan Han; Xiu-Qin Dai; He-Ping Zheng; Shao-Chun Chen; Bang-Yong Zhu; Gang Yong; Na Zhong; Li-Hua Hu; Wen-Ling Cao; Zhong-Jie Zheng; Feng Wang; Qi Zhi; Xiao-Yu Zhu; Xiang-Sheng Chen
Journal:  PLoS Med       Date:  2018-02-06       Impact factor: 11.069

5.  Antimicrobial susceptibility of Neisseria gonorrhoeae isolates in Vientiane, Lao PDR.

Authors:  Savandalath Phouangsouvanh; Mayfong Mayxay; Valy Keoluangkhot; Manivanh Vongsouvath; Viengmon Davong; David A B Dance
Journal:  J Glob Antimicrob Resist       Date:  2017-12-08       Impact factor: 4.035

6.  Multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae in Canada, 2012-2016.

Authors:  I Martin; P Sawatzky; V Allen; B Lefebvre; Lmn Hoang; P Naidu; J Minion; P Van Caeseele; D Haldane; R R Gad; G Zahariadis; A Corriveau; G German; K Tomas; M R Mulvey
Journal:  Can Commun Dis Rep       Date:  2019-02-07

7.  Systematic review and survey of Neisseria gonorrhoeae ceftriaxone and azithromycin susceptibility data in the Asia Pacific, 2011 to 2016.

Authors:  C R Robert George; Rodney P Enriquez; Barrie J Gatus; David M Whiley; Ying-Ru Lo; Naoko Ishikawa; Teodora Wi; Monica M Lahra
Journal:  PLoS One       Date:  2019-04-03       Impact factor: 3.240

Review 8.  Where have all the susceptible gonococci gone? A historical review of changes in MIC distribution over the past 75 years.

Authors:  Chris Kenyon; Jolein Laumen; Dorien Van Den Bossche; Christophe Van Dijck
Journal:  BMC Infect Dis       Date:  2019-12-27       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.